Peanut allergen powder

Peanut (Arachis hypogaea) allergen powder
Clinical data
Trade namesPalforzia
Other namesAR101, peanut allergen powder-dnfp
AHFS/Drugs.comProfessional Drug Facts
Routes of
administration		By mouth
ATC code
  • none
Legal status
Legal status

Peanut (Arachis hypogaea) Allergen Powder, sold under the brand name Palforzia, is an oral medication for the treatment of allergic reactions, including anaphylaxis, in children typically aged between four and 17 years of age who have confirmed cases of peanut allergy.[1][2] It is taken by mouth.[1]

Peanut (Arachis hypogaea) allergen powder is a powder that is manufactured from peanuts and packaged in pull-apart color-coded capsules for dose escalation and up-dosing, and in a sachet for maintenance treatment.[1] The powder is emptied from the capsules or sachet and mixed with a small amount of semisolid food, such as applesauce, yogurt, or pudding for consumption.[1][3]

The most common side effects of peanut (Arachis hypogaea) allergen powder are abdominal pain, vomiting, nausea, tingling in the mouth, itching (including in the mouth and ears), cough, runny nose, throat irritation and tightness, hives, wheezing and shortness of breath and anaphylaxis.[1][3] Peanut (Arachis hypogaea) allergen powder should not be administered to those with uncontrolled asthma.[1][3]

To mitigate the risk of anaphylaxis associated with peanut (Arachis hypogaea) allergen powder, the U.S. Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS).[3] Peanut (Arachis hypogaea) allergen powder is only available through specially certified healthcare providers, health care settings, and pharmacies to those who are enrolled in the REMS program.[3] The FDA is requiring that healthcare providers who prescribe peanut (Arachis hypogaea) allergen powder - and healthcare settings that dispense and administer peanut (Arachis hypogaea) allergen powder - are educated on the risk of anaphylaxis associated with its use.[3] In addition, the Initial Dose Escalation phase and first dose of each Up-Dosing level must only be administered to patients in a certified healthcare setting equipped to monitor patients and to identify and manage anaphylaxis.[3] Patients or their parents or caregivers must also be counseled on the need for the patients to have injectable epinephrine available for immediate use at all times, the need for continued dietary peanut avoidance, and how to recognize the signs and symptoms of anaphylaxis.[3]

In January 2020, the FDA approved the drug to Aimmune Therapeutics for mitigating "allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts."[3][4] It is the first drug approved for peanut allergies. It will not make allergic people to be able to eat normal amounts of peanuts, but will prevent allergies due to accidental eating.[5]

History

The effectiveness of peanut (Arachis hypogaea) allergen powder is supported by a randomized, double-blind, placebo-controlled study conducted in the U.S., Canada and Europe in approximately 500 peanut-allergic individuals.[3] Effectiveness was assessed by evaluating the percentage of study participants tolerating an oral challenge with a single 600 mg dose of peanut protein (twice the daily maintenance dose of peanut (Arachis hypogaea) allergen powder) with no more than mild allergic symptoms after six months of maintenance treatment.[3] The results showed that 67.2% of peanut (Arachis hypogaea) allergen powder recipients tolerated a 600 mg dose of peanut protein in the challenge, compared to 4.0% of placebo recipients.[3]

The safety of peanut (Arachis hypogaea) allergen powder was assessed in two double-blind, placebo-controlled studies in approximately 700 peanut-allergic individuals.[3]

On 21 December 2018, Aimmune Therapeutics applied Biologics License Application for Peanut (Arachis hypogaea) Allergen Powder-dnfp to the U.S. Food and Drug Administration.[4] On 13 September 2019, the FDA Allergenic Products Advisory Committee decided seven to two in favour of the approval.[6] The final approval was issued on 31 January 2020.[4]

On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Palforzia, intended for desensitizing children and adolescents to peanut allergy.[7]

Controversy

Although the FDA had decided the approval of Palforzia in 2019, the Institute for Clinical and Economic Review (ICER) reported that the clinical evidence is still insufficient.[6] A 2019 systematic review and meta-analysis of 12 clinical trials consisting of 1041 cases questioned the safety of oral peanut allergen treatment. The study concluded that the treatments "increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitisation."[8]

References

  1. 1 2 3 4 5 6 "Palforzia Initial Dose Escalation- peanut kit Palforzia (Level 1)- peanut powder Palforzia (Level 2)- peanut powder Palforzia (Level 3)- peanut kit Palforzia (Level 4)- peanut powder Palforzia (Level 5)- peanut powder Palforzia (Level 6)- peanut powder Palforzia (Level 7)- peanut kit Palforzia (Level 8)- peanut kit Palforzia (Level 9)- peanut powder Palforzia (Level 10)- peanut kit Palforzia (Level 11)- peanut powder". DailyMed. 14 February 2020. Retrieved 13 August 2020.
  2. ↑ "Palforzia". U.S. Food and Drug Administration (FDA). 7 February 2020. STN: 125696. Retrieved 12 February 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 "FDA approves first drug for treatment of peanut allergy for children". U.S. Food and Drug Administration (FDA) (Press release). 31 January 2020. Retrieved 31 January 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. 1 2 3 "Palforzia Approval Letter". U.S. Food and Drug Administration (FDA). 31 January 2020. Retrieved 13 February 2020.
  5. ↑ "The FDA has approved the first drug to treat peanut allergies". Science News. 4 February 2020. Retrieved 13 February 2020.
  6. 1 2 Eiwegger T, Anagnostou K, Arasi S, et al. (November 2019). "Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?". Journal of Allergy and Clinical Immunology. 145 (4): 1153–1156. doi:10.1016/j.jaci.2019.10.021. PMID 31678426.
  7. ↑ "Palforzia: Pending EC decision". European Medicines Agency (EMA). 16 October 2020. Retrieved 16 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ↑ Chu DK, Wood RA, French S, et al. (June 2019). "Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety". Lancet. 393 (10187): 2222–32. doi:10.1016/S0140-6736(19)30420-9. PMID 31030987. S2CID 131777064.

Further reading

  • "Peanut allergy". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02635776 for "Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (PALISADE)" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.